Abdominal sepsis

Acta Clinica Belgica

Volumn 53, Issue 4, 1998, Pages 251-254

  Peetermans, W E ^a   Hiele, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ABDOMINAL ABSCESS; ABDOMINAL DRAINAGE; ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; BACTEROIDES; DRUG MIXTURE; ENTEROCOCCUS; HOST RESISTANCE; HUMAN; PERITONITIS; REVIEW; SEPSIS;

EID: 0031757544     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754170     Document Type: Review

References (17)

1. Bhuva M, Ganger D, Jensen D. Spontaneous bacterial peritonitis: an update on evaluation, management and prevention. Am J Med. 1994; 97: 169-175.
2. Sawyer MD, Dunn DL. Antimicrobial treatment of intra-abdominal sepsis. Infect Dis Clin North Am. 1992; 6: 545-570.
3. Mc Clean KL, Sheehan GJ, Harding GKM. Intra-abdominal infection: a review. Clin Infect Dis. 1994; 19: 100-116.
4. Gorbach SL. Intra-abdominal infections. Clin Infect Dis. 1993; 17: 961-967.
5. Bartlett JG. Intra-abdominal sepsis. Med Clin North Am. 1995; 79: 599-617.
6. Montgomery RS, Wilson SE. Intra-abdominal abscesses: image-guided diagnosis and therapy. Clin Infect Dis. 1996; 23: 28-36.
7. Foitzik T, Runkel N. Intra-abdominal sepsis. Curr Op Infect Dis. 1996; 9: 353-358.
8. Walker AP, Krepel CJ, Gohr CM, Edmiston CE. Microflora of abdominal sepsis by locus of infection. J Clin Microbiol. 1994; 32: 557-558.
9. Grant SW, Hopkins J, Wilson SE. Operative site bacteriology as an indicator of prognostic infectious complications in elective colorectal surgery. Am Surg. 1995; 61: 856-861.
10. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997; 18: 275-291.
11. Verbist L, Verhaegen J, Wouters Ch, Vandenhove G and a multicenter study group. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalized patients. J Antimicrob Chemother. 1996; 37: 285-293.
12. Pierard D, De Meyer A, Rosseel P, et al. In vitro activity of amoxicillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey. Acta Clin Belg. 1996; 51: 70-79.
13. Jacobs MR, Spangler SK, Appelbaum PC. Beta-lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents. Eur J Clin Microbiol Infect Dis. 1992; 11: 1081-1093.
14. Bohnen JMA, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg. 1992; 127: 83-89.
15. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin/tazobactam versus imipenem/cilastatin for treatment of intra-abdominal infections. Antimicrob Ag Chemother. 1992; 36: 2766-2773.
16. Polk HC, Fink MP, La Verdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infections. Am Surg. 1993; 59: 598-605.
17. Brismar B, Malmborg S, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother. 1995; 35: 139-148.